Task E03: Lead Optimization Screening Assays for Safety Profiling

任务 E03：安全性分析的先导物优化筛选分析

• 批准号: 9916136
• 负责人: JACOB BODE
• 金额: $ 10.3万
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-06 至 2020-03-05
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9916136
• 关键词: Antimicrobial Resistance; Biological Assay; Chemistry; Communicable Diseases; DNA Viruses; Development; Development Plans; Drug Kinetics; Evaluation; Gram-Negative Bacteria; In Vitro; Interventional Agent Development; Lead; Microbiology; RNA Viruses; Safety; Services; Staphylococcus aureus; Support Contracts; Therapeutic; Toxicology; Toxin; fungus; in vivo; lead optimization; pathogen; pre-clinical; product development; programs; screening; therapeutic development

The Non-clinical Services for Development of Interventional Agents for Infectious Diseases program provides services to facilitate preclinical product development of promising therapeutics for infectious disease-causing pathogens and/or toxins. Services include: preclinical product development planning and evaluation; lead identification and development; chemistry and GMP manufacturing; in vitro and in vivo preclinical microbiological, safety, toxicology and pharmacokinetics.

传染病介入性药物开发的非临床服务项目提供服务，以促进有前途的传染病病原体和/或毒素疗法的临床前产品开发。服务内容包括：临床前产品开发规划与评估；领导识别和开发；化学和GMP制造；体外和体内临床前微生物学，安全性，毒理学和药代动力学。